A faulty hemagglutinin inhibition assay may be the reason underlying the failure of a Phase II clinical trial of Intercell AG's investigational Vaccine Enhancement Patch (VEP) for H5N1 influenza. (BioWorld International)
Marinomed Biotechnologie GmbH is banking an undisclosed up-front payment of several million Euros on the back of a distribution deal it has entered with Boehringer Ingelheim GmbH involving its antiviral nasal spray for the common cold. (BioWorld International)
Shares in Diamyd Therapeutics AB surged by around 30 percent Tuesday on news of a potential $625 million partnering deal with Ortho-McNeil-Janssen Pharmaceuticals (OMJP) Inc., involving its Phase III therapeutic vaccine for Type I diabetes, which is also called Diamyd. The Stockholm, Sweden-based company is getting $45 million up front and could earn up to $580 million more in development and commercial milestones. It would also receive tiered royalties on product sales. (BioWorld International)
